Cipher Pharmaceuticals Inc (CPH) Stock Price Down 4.4%

Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) traded down 4.4% on Thursday . The stock traded as low as C$4.31 and last traded at C$4.35. 12,715 shares changed hands during trading, an increase of 38% from the average session volume of 9,231 shares. The stock had previously closed at C$4.55.

A number of research firms have recently commented on CPH. TD Securities increased their price objective on Cipher Pharmaceuticals from C$5.50 to C$6.50 in a report on Monday, August 14th. Bloom Burton downgraded Cipher Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 14th.

The firm’s market cap is $116.33 million. The company’s 50-day moving average price is $4.78 and its 200-day moving average price is $5.05.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.chaffeybreeze.com/2017/10/12/cipher-pharmaceuticals-inc-cph-stock-price-down-4-4.html.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc, together with its subsidiaries, operates as a specialty pharmaceutical dermatology company in South America, Canada, and the United States. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.

Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply